How A New Ben Affleck Campaign At Aflac (AFL) Has Changed Its Investment Story

• In early September 2026, Aflac and artist-led studio Artists Equity announced a new long-term partnership bringing Ben Affleck together with the Aflac Duck in a nationwide 360-degree advertising campaign aimed at educating consumers about supplemental health insurance and out-of-pocket medical costs.
• This collaboration blends a well-known Hollywood creator with Aflac’s established mascot, potentially giving the insurer a fresh platform to explain how supplemental coverage fits alongside traditional health insurance.
• Next, we’ll examine how this high-profile Ben Affleck campaign could influence Aflac’s investment narrative, particularly around product awareness and U.S. growth.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

Aflac Investment Narrative Recap

To own Aflac, you need to believe its core supplemental insurance franchise can keep generating solid cash while management manages Japan exposure and sluggish U.S. sales. The Ben Affleck campaign looks incremental rather than a material near term catalyst, but it could modestly support efforts to reaccelerate U.S. growth, one of the key execution swing factors, without changing the central risks tied to Japan premiums, expenses and currency volatility.

The recent launch of Aflac’s Accident Insurance plan across 32 states, which emphasizes cash benefits for out of pocket costs, lines up directly with the Affleck and Aflac Duck campaign’s educational focus. Together, richer accident coverage and higher profile marketing could work in tandem to raise awareness of supplemental products among U.S. workers and employers, potentially helping address the concern that U.S. sales growth has been running below historical levels.

Yet behind the celebrity campaign, investors should also be aware of how ongoing weakness in Japan premiums and yen volatility could...

Read the full narrative on Aflac (it's free!)

Aflac's narrative projects $17.5 billion revenue and $3.6 billion earnings by 2029. This implies revenues declining by 1.1% per year and an earnings decrease of $1.0 billion from $4.6 billion today.

Uncover how Aflac's forecasts yield a $117.71 fair value, in line with its current price.

Exploring Other Perspectives

Simply Wall St Community members see Aflac’s fair value between US$117.71 and US$169.38 across 2 independent views, underlining how far opinions can stretch. Against that backdrop, Aflac’s reliance on Japan where premiums are shrinking and currency swings affect reported earnings may be an important factor you compare across these viewpoints.

Explore 2 other fair value estimates on Aflac - why the stock might be worth just $117.71!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Aflac research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Aflac research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aflac's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com